Attralus Therapeutics
Jeffery W. Kelly is Professor of Chemistry at The Scripps Research Institute. He is a leading expert in protein misfolding disorders and discovered the first approved drug (tafamidis vyndaqel; Pfizer) for transthyretin amyloidosis. He was a Co-founder of FoldRx (acquired by Pfizer) and Proteostasis.
He has served as a board member at Yumanity, Proteostasis, Scripps, George Hewitt Foundation, and Amyloidosis Research Consortium.
This person is not in the org chart
This person is not in any offices
Attralus Therapeutics
Attralus is a clinical stage biopharmaceutical company focused on creating transformative medicines to improve the lives of patients with systemic amyloidosis.